Biocartis Group NV announced that four study abstracts on Idylla? have been selected for poster presentations at the international ESMO (European Society of Molecular Oncology) congress, taking place between October 20, 2023 to October 24, 2023 in Madrid (Spain). The studies show excellent data for the Idylla?

GeneFusion Assay and Idylla? EGFR Mutation Assay. Three studies demonstrate that the Idylla?

GeneFusion and EGFR Mutation Assays offer a rapid, sensitive and specific method for lung sample profiling in routine practice. The first study prospectively tested lung cancer samples on the Idylla? Platform as part of routine lung profiling locally and from over 60 UK hospitals.

The investigators tested over 5,000 cases and demonstrated that the Idylla? GeneFusion Assay had the expected rate of positivity and a low failure rate. Moreover, the Assay allowed testing to be successfully completed in samples unsuitable for NGS due to low tumor burden.

The second abstract presents the results of a multicenter study that was conducted in a routine clinical setting involving 12 clinical centers across Europe. Providing high sensitivity and specificity values for all biomarkers, together with a low failure rate and rapid turnaround time (within 3 hours), the investigators concluded that the Idylla? GeneFusion Assay technology has emerged as a highly relevant, time efficient and upfront screening tool on FFPE samples.

The third abstract presents the results of the ORIGEN study, a multicenter study on the prevalence of EGFR gene mutations in patients with early-stage resectable non-small cell lung cancer in Spain (in collaboration with AstraZeneca Spain). The investigators demonstrated a 15% frequency of EGFR mutations, with the most frequent being exon 19 deletions and the presence of the L858R mutation, which is in line with other data reported in Spain in advanced NSCLC. These results reinforce the importance of performing EGFR testing in early-stage NSCLC to predict the most appropriate treatment options.

The fourth abstract describes a research project that aims to identify the feasibility of the Idylla? GeneFusion Assay in detecting RET fusions in Papillary Thyroid Cancer (PTC).